<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39414922</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Corticosteroids for hospitalized patients with severe/critical COVID-19: a retrospective study in Chongqing, China.</ArticleTitle><Pagination><StartPage>24317</StartPage><MedlinePgn>24317</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24317</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75926-9</ELocationID><Abstract><AbstractText>Corticosteroids have always been recommended for severe cases of COVID-19. However, the efficacy of treatment with corticosteroids for COVID-19 during the SARS-CoV-2 omicron outbreak in China has not been reported. Clinical data from 406 patients hospitalized for severe/critical COVID-19 from December 2022 to January 2023 at six hospitals in Chongqing were retrospectively analyzed. The primary outcome was all-cause mortality at 28 days in the groups with and without corticosteroids treatment after propensity score matching (PSM). Secondary outcomes were to compare in-hospital mortality and length of survival time with corticosteroids and those without corticosteroids. This study included 406 patients with severe or critical COVID-19, divided into the corticosteroids group (231, 56.9%) and non-corticosteroids group (175, 43.1%). After PSM, the use of corticosteroids did not reduce all-cause mortality at 28 days (42.5% vs. 39.1%). Univariate analysis showed that corticosteroids were not associated with improved all-cause mortality at 28 days [hazard ratio (HR), 1.019; 95% confidence interval (CI), 0.639-1.623; p = 0.938]. Multivariate analysis showed similar results (HR, 1.047; 95% CI, 0.633-1.732; p = 0.858). Among non-survivors, the survival time was significantly larger in those who received corticosteroids compared with the non-corticosteroid users [median 13 (IQR 6.5-15.5) vs. 6 (4-11.25), p = 0.007]. The use of systemic corticosteroids in severe/critical COVID-19 may provide certain potential survival benefits but does not improve prognosis.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhuang</LastName><ForeName>Rongjuan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Xia</LastName><ForeName>Hongli</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Practice, People's Hospital of Chongqing Heuchan, Chongqing, 401520, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zong</LastName><ForeName>Kaican</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Hailang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Zhuzhou Central Hospital, Central South University, Zhuzhou, 412007, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Huizi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Lan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hongwei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Chun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Affiliated University Town Hospital of Chongqing Medical University, Chongqing, 401331, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, People's Hospital of Shapingba District, Chongqing, 400030, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Shuliang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, People's Republic of China. guoshul666@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="Y">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="Y">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Corticosteroids</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>23</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39414922</ArticleId><ArticleId IdType="pmc">PMC11484943</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75926-9</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75926-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Markov, P. V., Katzourakis, A. &amp; Stilianakis, N. I. Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity. Nat. Rev. Microbiol.20, 251–252 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8919145</ArticleId><ArticleId IdType="pubmed">35288685</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalali, N. et al. Increased household transmission and immune escape of the SARS-CoV-2 omicron compared to Delta variants. Nat. Commun.13, 5706 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9520116</ArticleId><ArticleId IdType="pubmed">36175424</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO &amp; Coronavirus (COVID-19) Dashboard.</Citation></Reference><Reference><Citation>RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl. J. Med.384, 693–704 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang, Z. et al. Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels. Int. J. Biol. Sci.16, 2382–2391 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7378642</ArticleId><ArticleId IdType="pubmed">32760206</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranjbar, K. et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect. Dis.21, 337 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8035859</ArticleId><ArticleId IdType="pubmed">33838657</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan, Y., Shang, J., Gu, Y., Huang, Q. &amp; Xie, J. Efficacy of corticosteroid in patients with COVID-19: a multi-center retrospective study and meta-analysis. J. Med. Virol.93, 4292–4302 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014848</ArticleId><ArticleId IdType="pubmed">33666250</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, X. et al. Effect of corticosteroids in patients with COVID-19: a bayesian network meta-analysis. Int. J. Infect. Dis.125, 84–92 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9581790</ArticleId><ArticleId IdType="pubmed">36272700</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderbeke, L. et al. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nat. Commun.12, 4117 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8257697</ArticleId><ArticleId IdType="pubmed">34226537</ArticleId></ArticleIdList></Reference><Reference><Citation>Remmington, C. et al. Steroid exposure and outcome in COVID-19 pneumonia. BJA Open.5, 100128 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9886648</ArticleId><ArticleId IdType="pubmed">36744291</ArticleId></ArticleIdList></Reference><Reference><Citation>Patoulias, D. &amp; Dimosiari, A. Intravenous pulse methylprednisolone for the treatment of severe COVID-19. Eur. J. Intern. Med.S0953-6205 (23), 00048–00041. 10.1016/j.ejim.2023.02.008 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9935278</ArticleId><ArticleId IdType="pubmed">36822893</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, S. Corticosteroids for non-severe COVID-19 infections? Too early to conclude. Korean J. Intern. Med.38, 144–146 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9993106</ArticleId><ArticleId IdType="pubmed">36864598</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395, 1054–1062 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, T. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ (Clinical Res. ed.). 368, m1091 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190011</ArticleId><ArticleId IdType="pubmed">32217556</ArticleId></ArticleIdList></Reference><Reference><Citation>China, N. H. C. of the P. R. of &amp; Medicine, N. A. of T. C. Translation: diagnosis and treatment protocol for COVID-19 (Trial Version 9). Infect. Microbes Dis.4, 94 (2022).</Citation></Reference><Reference><Citation>China, N. H. C. of the P. R. of &amp; Medicine, N. A. of T. C. Translation: diagnosis and treatment protocol for COVID-19 (Trial Version 10). Infect. Microbes Dis.5, 3 (2023).</Citation></Reference><Reference><Citation>Jianping, Z. et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Chin. J. Tuberculosis Respiratory Dis.43, 183–184 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32164084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan, S. et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br. J. Haematol.189, 428–437 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262036</ArticleId><ArticleId IdType="pubmed">32297671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mager, D. E., Lin, S. X., Blum, R. A., Lates, C. D. &amp; Jusko, W. J. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J. Clin. Pharmacol.43, 1216–1227 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14551176</ArticleId></ArticleIdList></Reference><Reference><Citation>Overview of national treatment. and surveillance data for novel coronavirus infection. https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202301/t20230125_263519.html.&lt;published in 25 January 2023&gt;.</Citation></Reference><Reference><Citation>Uraki, R. et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature. 607, 119–127 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10579982</ArticleId><ArticleId IdType="pubmed">35576972</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 584, 430–436 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, D. J. et al. COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022. MMWR Morb. Mortal. Wkly Rep.71, 545–548 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9020860</ArticleId><ArticleId IdType="pubmed">35421076</ArticleId></ArticleIdList></Reference><Reference><Citation>McMenamin, M. E. et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect. Dis.22, 1435–1443 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9286709</ArticleId><ArticleId IdType="pubmed">35850128</ArticleId></ArticleIdList></Reference><Reference><Citation>de Mélo Silva Júnior, M. L., de Souza, L. M. A., Dutra, R. E. M. C., de Valente, R. G., Melo, T. S. &amp; M. &amp; Review on therapeutic targets for COVID-19: insights from cytokine storm. Postgrad. Med. J.97, 391–398 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10016930</ArticleId><ArticleId IdType="pubmed">33008960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta, N., Mazer-Amirshahi, M., Alkindi, N. &amp; Pourmand, A. Pharmacotherapy in COVID-19; a narrative review for emergency providers. Am. J. Emerg. Med.38, 1488–1493 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158837</ArticleId><ArticleId IdType="pubmed">32336586</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller, M. J. et al. Effect of systemic glucocorticoids on mortality or mechanical ventilation in patients with COVID-19. J. Hosp. Med.15, 489–493 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7518134</ArticleId><ArticleId IdType="pubmed">32804611</ArticleId></ArticleIdList></Reference><Reference><Citation>Dequin, P. F. et al. Effect of hydrocortisone on 21-Day mortality or respiratory support among critically ill patients with COVID-19: a Randomized Clinical Trial. Jama. 324, 1298–1306 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489432</ArticleId><ArticleId IdType="pubmed">32876689</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei, L. et al. Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin in 1142 patients with coronavirus disease 2019: a systematic review and meta-analysis. Pol. Archives Intern. Med.130, 726–733 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32749826</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, H. M. et al. Effect of methylprednisolone in severe and critical COVID-19: analysis of 102 cases. World J. Clin. Cases. 8, 5952–5961 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723720</ArticleId><ArticleId IdType="pubmed">33344594</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeronimo, C. M. P. et al. Methylprednisolone as adjunctive therapy for patients hospitalized with Coronavirus Disease 2019 (COVID-19; Metcovid): a Randomized, Double-blind, phase IIb, placebo-controlled trial. Clin. Infect. Dis.72, e373–e381 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454320</ArticleId><ArticleId IdType="pubmed">32785710</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno, G. et al. Corticosteroid treatment and mortality in mechanically ventilated COVID-19-associated acute respiratory distress syndrome (ARDS) patients: a multicentre cohort study. Ann. Intensiv. Care.11, 159 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8617372</ArticleId><ArticleId IdType="pubmed">34825976</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, J., Zheng, X., Huang, Y., Shan, H. &amp; Huang, J. Successful use of methylprednisolone for treating severe COVID-19. J. Allergy Clin. Immunol.146, 325–327 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7256545</ArticleId><ArticleId IdType="pubmed">32479759</ArticleId></ArticleIdList></Reference><Reference><Citation>Papamanoli, A. et al. High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia. Eur. J. Clin. Invest.51, e13458 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744876</ArticleId><ArticleId IdType="pubmed">33219551</ArticleId></ArticleIdList></Reference><Reference><Citation>Corral-Gudino, L. et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia: an open-label randomized trial (GLUCOCOVID). Wien Klin. Wochenschr. 133, 303–311 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854876</ArticleId><ArticleId IdType="pubmed">33534047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, C. et al. Risk factors Associated with Acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med.180, 934–943 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Edalatifard, M. et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur. Respir J.56, 2002808 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7758541</ArticleId><ArticleId IdType="pubmed">32943404</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty, R. R. &amp; Meher, B. R. Biswa Mohan Padhy, null Effectiveness of pulse dose methyl prednisolone in management of COVID 19: A systematic review and meta-analysis of observational studies. Journal of Pharmacy &amp; Pharmaceutical Sciences: A Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques 25, 110–123 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35364003</ArticleId></ArticleIdList></Reference><Reference><Citation>Corral-Gudino, L. et al. Effect of intravenous pulses of methylprednisolone 250 mg versus dexamethasone 6 mg in hospitalised adults with severe COVID-19 pneumonia: an open-label randomised trial. Eur. J. Clin. Invest.53, e13881 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538428</ArticleId><ArticleId IdType="pubmed">36169086</ArticleId></ArticleIdList></Reference><Reference><Citation>Granholm, A. et al. Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Intensive Care Med.48, 580–589 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8970069</ArticleId><ArticleId IdType="pubmed">35359168</ArticleId></ArticleIdList></Reference><Reference><Citation>Maskin, L. P. et al. High- Versus Low-Dose Dexamethasone for the treatment of COVID-19-Related Acute Respiratory Distress Syndrome: a Multicenter, Randomized Open-label clinical trial. J. Intensive Care Med.37, 491–499 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926919</ArticleId><ArticleId IdType="pubmed">34898320</ArticleId></ArticleIdList></Reference><Reference><Citation>Angus, D. C. et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain Randomized Clinical Trial. Jama. 324, 1317–1329 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489418</ArticleId><ArticleId IdType="pubmed">32876697</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between Administration of Systemic Corticosteroids and Mortality among critically ill patients with COVID-19: a Meta-analysis. Jama. 324, 1330–1341 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri, D. et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med.47, 521–537 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054852</ArticleId><ArticleId IdType="pubmed">33876268</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell, C. D., Millar, J. E. &amp; Baillie, J. K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet (London England). 395, 473–475 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7134694</ArticleId><ArticleId IdType="pubmed">32043983</ArticleId></ArticleIdList></Reference><Reference><Citation>Ezeokoli, O. T., Gcilitshana, O. &amp; Pohl, C. H. Risk factors for fungal co-infections in critically ill COVID-19 patients, with a focus on immunosuppressants. J. Fungi (Basel Switzerland). 7, 545 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8304654</ArticleId><ArticleId IdType="pubmed">34356924</ArticleId></ArticleIdList></Reference><Reference><Citation>Morton, C. O., Griffiths, J. S., Loeffler, J., Orr, S. &amp; White, P. L. Defective antifungal immunity in patients with COVID-19. Front. Immunol.13, 1080822 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9750792</ArticleId><ArticleId IdType="pubmed">36531987</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca, G. et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol.2, e465–e473 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7430344</ArticleId><ArticleId IdType="pubmed">32835256</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>